Stockreport

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 [Yahoo! Finance]

EyePoint Pharmaceuticals, Inc.  (EYPT) 
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained [Read more]